Zobrazeno 1 - 10
of 62
pro vyhledávání: '"M. Neil Reaume"'
Autor:
Michael Fung-Kee-Fung, Rachel S. Ozer, Bill Davies, Stephanie Pick, Kate Duke, David J. Stewart, M. Neil Reaume, Marcus Ward, Katelyn Balchin, Robert M. MacRae, Shannon Nelson, Julie Renaud, Dennis Garvin, Suzanne Madore, Jason R. Pantarotto
Publikováno v:
Current Oncology, Vol 29, Iss 6, Pp 3983-3995 (2022)
Ambulatory cancer centers face a fluctuating patient demand and deploy specialized personnel who have variable availability. This undermines operational stability through the misalignment of resources to patient needs, resulting in overscheduled clin
Externí odkaz:
https://doaj.org/article/fd015d0cc3ea433dae9036710fb08968
Autor:
Ambica Parmar, Sunita Ghosh, Arjun Sahgal, Aly‐Khan A. Lalani, Aaron R. Hansen, M. Neil Reaume, Lori Wood, Naveen S. Basappa, Daniel Y. C. Heng, Jeffrey Graham, Christian Kollmannsberger, Denis Soulières, Rodney H. Breau, Simon Tanguay, Anil Kapoor, Frédéric Pouliot, Georg A. Bjarnason
Publikováno v:
Cancer Reports, Vol 6, Iss 3, Pp n/a-n/a (2023)
Abstract Background Brain metastases (BM) in metastatic renal cell carcinoma (mRCC) have been reported to be present in up to 25% of patients diagnosed with mRCC. There is limited published literature evaluating the role of routine intra‐cranial im
Externí odkaz:
https://doaj.org/article/092dbeb3dad24a6c923e32e6476ded01
Autor:
Jeffrey Sulpher, Franco Dattilo, Susan Dent, Michele Turek, M. Neil Reaume, Christopher Johnson
Publikováno v:
Case Reports in Oncological Medicine, Vol 2014 (2014)
A 49-year-old patient with metastatic carcinoma of the bladder and no prior history of heart disease presented with diffuse ST elevation, elevated troponins, and biventricular dysfunction requiring intensive care unit admission and inotropic support
Externí odkaz:
https://doaj.org/article/f2416804e86742e2a189223603001370
Autor:
Karim Fizazi, Josep M. Piulats, M. Neil Reaume, Peter Ostler, Ray McDermott, Joel R. Gingerich, Elias Pintus, Srikala S. Sridhar, Richard M. Bambury, Urban Emmenegger, Henriette Lindberg, David Morris, Franco Nolè, John Staffurth, Charles Redfern, María I. Sáez, Wassim Abida, Gedske Daugaard, Axel Heidenreich, Laurence Krieger, Brieuc Sautois, Andrea Loehr, Darrin Despain, Catherine A. Heyes, Simon P. Watkins, Simon Chowdhury, Charles J. Ryan, Alan H. Bryce
Publikováno v:
New England Journal of Medicine. 388:719-732
Autor:
Oliver Sartor, Theodore G. Karrison, Howard M. Sandler, Leonard G. Gomella, Mahul B. Amin, James Purdy, Jeff M. Michalski, Mark G. Garzotto, Nadeem Pervez, Alexander G. Balogh, George B. Rodrigues, Luis Souhami, M. Neil Reaume, Scott G. Williams, Raquibul Hannan, Christopher U. Jones, Eric M. Horwitz, Joseph P. Rodgers, Felix Y. Feng, Seth A. Rosenthal
Publikováno v:
European Urology.
Autor:
Martin R, Stockler, Andrew J, Martin, Ian D, Davis, Haryana M, Dhillon, Stephen D, Begbie, Kim N, Chi, Simon, Chowdhury, Xanthi, Coskinas, Mark, Frydenberg, Wendy E, Hague, Lisa G, Horvath, Anthony M, Joshua, Nicola J, Lawrence, Gavin M, Marx, John, McCaffrey, Ray, McDermott, Margaret, McJannett, Scott A, North, Francis, Parnis, Wendy R, Parulekar, David W, Pook, M Neil, Reaume, Shahneen, Sandhu, Alvin, Tan, Thean Hsiang, Tan, Alastair, Thomson, Francisco, Vera-Badillo, Scott G, Williams, Diana G, Winter, Sonia, Yip, Alison Y, Zhang, Robert R, Zielinski, Christopher J, Sweeney
Publikováno v:
Journal of Clinical Oncology. 40:837-846
PURPOSE We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality of life (HRQL). METHODS HRQL
Autor:
Ambica Parmar, Sunita Ghosh, Arjun Sahgal, Aly‐Khan A. Lalani, Aaron R. Hansen, M. Neil Reaume, Lori Wood, Naveen S. Basappa, Daniel Y. C. Heng, Jeffrey Graham, Christian Kollmannsberger, Denis Soulières, Rodney H. Breau, Simon Tanguay, Anil Kapoor, Frédéric Pouliot, Georg A. Bjarnason
Publikováno v:
Cancer Reports. 6
Brain metastases (BM) in metastatic renal cell carcinoma (mRCC) have been reported to be present in up to 25% of patients diagnosed with mRCC. There is limited published literature evaluating the role of routine intra-cranial imaging for the screenin
Autor:
Stephen Begbie, Wendy R. Parulekar, Scott North, Francis Parnis, Alvin Tan, David Pook, John McCaffrey, Xanthi Coskinas, Thean Hsiang Tan, M. Neil Reaume, Scott Williams, Francisco E. Vera-Badillo, Alastair Thomson, Emily Tu, Shahneen Sandhu, Alison Yan Zhang, Andrew J. Martin, Anthony M. Joshua, Lisa G. Horvath, Nicola Jane Lawrence, Margaret McJannett, Wendy Hague, Martin R. Stockler, Ian D. Davis, Christopher Sweeney, Robert Zielinski, Ray McDermott, Mark Frydenberg, Simon Chowdhury, Gavin Marx, Kim N. Chi, Sonia Yip
Publikováno v:
European Urology. 80:275-279
Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than men with de novo metastatic disease and often have a low burden of disease on conventional imaging. Some have disease amen
Autor:
Christian Kollmannsberger, Ben Tran, Aaron R. Hansen, Guillermo Velasco, Daniel Y.C. Heng, Daniel Vilarim Araujo, M. Neil Reaume, Takeshi Yuasa, Connor Wells, Georg A. Bjarnason, Benoit Beuselinck, Chun Loo Gan, D. Scott Ernst, Flora Yan, Shaan Dudani, Frede Donskov, Sumanta K. Pal, Thomas Powles, Nazli Dizman, Toni K. Choueiri
Publikováno v:
Araujo, D V, Wells, J C, Hansen, A R, Dizman, N, Pal, S K, Beuselinck, B, Donskov, F, Gan, C L, Yan, F, Tran, B, Kollmannsberger, C K, de Velasco, G, Yuasa, T, Reaume, M N, Ernst, D S, Powles, T, Bjarnason, G A, Choueiri, T K, Heng, D Y C & Dudani, S 2021, ' Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis ', Journal of Geriatric Oncology, vol. 12, no. 5, pp. 820-826 . https://doi.org/10.1016/j.jgo.2021.02.022
5068 Background: Anti-PD-1/PD-L1 immune-checkpoint inhibitors (ICI) are now a standard of care in metastatic renal cell carcinoma (mRCC). Older adults were underrepresented in registration trials and given that immunological senescence may affect the
Autor:
Alan Haruo Bryce, Josep M. Piulats, M. Neil Reaume, Peter James Ostler, Raymond S. McDermott, Joel Roger Gingerich, Elias Pintus, Srikala S. Sridhar, Wassim Abida, Gedske Daugaard, Axel Heidenreich, Laurence E. M. Krieger, Brieuc Sautois, Andrea Loehr, Darrin Despain, Jowell Go, Simon Paul Watkins, Simon Chowdhury, Charles J. Ryan, Karim Fizazi
Publikováno v:
Journal of Clinical Oncology. 41:18-18
18 Background: TRITON3 (NCT02975934) is a randomized, multicenter, open-label, phase 3 study of rucaparib vs physician’s choice (docetaxel [DTX], abiraterone [ABI] or enzalutamide [ENZ]) in patients (pts) with chemotherapy-naïve mCRPC with BRCA1/2